

COMMUNITY ACCESS NATIONAL NETWORK



Monkeypox (MPV) - Patient Awareness Project

A Patient's Guide to MPV: Report Nº 5

Monkeypox (MPV) Timeline & Top-line Numbers in the United States

MPV Timeline



May 9th, 2022 May 17th, 2022

First cases of current Monkeypox Virus (MPV) outbreak begin appearing in Europe.



The First case of MVP is diagnosed in the United States.



May 22nd, 2022

The JYNNEOS vaccine is administered as prophylaxis against MPV.



May 28nd, 2022

TPOXX (tecovirimat) is first prescribed as an investigational treatment for MPV in patients with severe symptoms of the disease, are immunocompromised, or have other concurrent conditions that may present complications.



Jul 24th, 2022

For the first time, Black Americans represent the highest percentage of new MPV diagnoses.



Aug 1st, 202

FDA allows JYNNEOS vaccine for subcutaneous administration in patients aged <18, and intradermal administration in a series of two doses in patients aged 18+ to increase vaccine supply.



Aug 9th, 2022

U.S. government declares MPV a Public Health Emergency



Aug 20th, 2022

Positive MPV diagnoses peak in MMWR Week 33, with 4,126 cases identified in a single week.



Sept 12th, 2022

CDC announces the first death due to MPV in a severely immunocompromised patient in Los Angeles County.



Oct 12th, 2022

CDC releases report finding 80% HIV co-infection in a cohort of patients hospitalized for severe MPV.



Nov 28th, 2022

World Health Organization recommends "MPOX" as a new name for MPV in an effort to combat racist and stigmatizing language and associations.



Jan 31st, 2023

The U.S. MPV Public Health Emergency is officially ended.

MPV Top-line Numbers

Total Cases:

30,193*

Total Hospitalizations:

No Data

Total Deaths:

32**

Total Vaccines Administered:

1,191,641***

Total First Doses Administered:

735,586

Total Second Doses Administered:

453,822



Date range on the numbers:

May 9, 2022 - February 15, 2023

- * CDC does not report total MPV diagnoses by Race demographic, instead presenting the data as a percentage of total cases. We achieved a cumulative average by averaging those percentages from the first reporting week to the most recent.
- ** To protect the privacy of patients, CDC does not report any demographic data for those patients who died as a result of MPV infection.
- *** MPV vaccines were originally offered as a single-dose administration. Split doses were introduced to preserve a limited supply of vaccines.

This makes the exact calculation of the percentage of persons who've received split doses and second doses difficult to accurately report.

MPV Demographics Snapshot

- Cisgender Men were the likeliest to be diagnosed with MPV.
- Black Americans accounted for a third (33.7%) of cumulative diagnoses in the United States over the reporting period.
- ► Transgender Women were more likely than Transgender Men to be diagnosed with MPV.
- Cisgender Male patients were more likely to complete the full series of MPV vaccines than patients of Female or Unknown sex.